Panangin (Magnesium Aspartate, Potassium Aspartate)

Magnesium aspartate and Potassium aspartate, the active ingredient in Panangin, is a mineral supplement presented as a intravenous solution for electrolyte replenishment in clinical settings. It is used to correct magnesium and potassium deficits and support cardiac and neuromuscular function in hospitalized patients. GNH USA supplies Panangin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and oncology centres worldwide.

GNH USA supplies Panangin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and oncology centres worldwide.

Panangin is a mineral supplement that addresses electrolyte imbalances in several clinical situations.

- Hypokalemia: helps restore normal potassium levels and supports cardiac rhythm stability. - Hypomagnesemia: contributes to the correction of low magnesium concentrations and aids neuromuscular function. - Post‑operative electrolyte management: assists in maintaining electrolyte homeostasis after surgery. - Cardiac arrhythmia prophylaxis: provides necessary electrolytes to reduce the risk of rhythm disturbances. - Intensive care unit (ICU) support: supplies essential magnesium and potassium for critically ill patients.

Adverse reactions to Panangin are generally related to the intravenous route and electrolyte shifts.

Common Side Effects: - Injection site discomfort: mild pain or erythema at the infusion site. - Transient flushing: brief sensation of warmth or redness. - Nausea: occasional mild nausea during or after infusion. - Headache: mild headache reported by some patients.

Serious or Rare Side Effects: - Hypermagnesemia: elevated serum magnesium causing hypotension, bradycardia, or respiratory depression. - Hyperkalemia: high potassium levels leading to cardiac arrhythmias. - Allergic reaction: rash, itching, or anaphylaxis in sensitive individuals. - Vein thrombosis: clot formation at the infusion site.

When using Panangin, clinicians should assess patient-specific factors and monitor electrolyte levels closely.

- Renal impairment: adjust dosing and monitor serum magnesium and potassium. - Cardiac disease: observe cardiac rhythm and avoid rapid infusion rates. - Concomitant electrolyte therapy: coordinate with other magnesium or potassium products to prevent excess. - Pregnancy and lactation: use only if clearly indicated and benefits outweigh risks. - Pediatric use: dose must be individualized by a qualified health professional. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Panangin may interact with other medications that influence electrolyte balance or cardiac conduction.

Major Interactions (Avoid): - Digoxin: increased risk of digoxin toxicity due to altered potassium levels. - Calcium channel blockers: additive effects on cardiac conduction and blood pressure. - Loop diuretics: may exacerbate electrolyte loss if not monitored.

Moderate Interactions (Monitor Closely): - ACE inhibitors: potential for hyperkalemia, requiring serum potassium monitoring. - Beta‑blockers: may enhance bradycardic effects when combined with high magnesium levels. - NSAIDs: can affect renal handling of electrolytes, necessitating closer observation.